http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005054302-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68459a749198476399d79f1726e8e36a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7540da0bf2b99c607039693df49f26f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G63-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G63-00
filingDate 2004-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce06de1ae783afa8332bf25de98189a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4282d7b5e00fb3e5243fca4d674aacf8
publicationDate 2005-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005054302-A1
titleOfInvention Drug carrier and process for producing the same
abstract It is intended to provide a modified water-soluble hyaluronic acid practically usable as a drug carrier and a process for producing the same. It is found out that a modified water-soluble hyaluronic acid, which is obtained by introducing a hydrazide-containing group to the carboxy group of hyaluronic acid or glucuronic acid that is a derivative thereof to an extent of 55% by mol or higher in a solvent mixture of water with a polar organic solvent, can show a retention time in the blood extended to a practically usable level which cannot be achieved by the existing modified water-soluble hyaluronic acids.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9243077-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012118189-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015527391-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8519051-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-6141180-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2012118189-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4781435-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006028110-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9987367-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008047948-A1
priorityDate 2003-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0959303-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0016818-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444791
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127394906
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397529
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398302

Total number of triples: 31.